Epidemiological evidence has shown that abdominal obesity is closely associated with the development of cardiovascular (CV) disease, suggesting that it might be considered as an independent CV risk factor. However, the pathophysiological mechanisms responsible for the association between these 2 clinical entities remain largely unknown. Adipocytes are considered able to produce and secrete chemical mediators known as “adipokines” that may exert several biological actions, including those on heart and vessels. Of interest, a different adipokine profile can be observed in the plasma of patients with obesity or metabolic syndrome compared with healthy controls. We consider the main adipokines, focusing on their effects on the vascular wall and analyzing their role in CV pathophysiology.
World Health Organization. World Health Statistics 2012. Geneva: World Health Organization; 2012.
2.
World Health Organization. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva: World Health Organization; 2009.
3.
WhitlockGLewingtonSSherlikerP. Body-mass index and cause-specific mortality in 900000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–1096.
4.
PhillipsSDRobertsWC. Comparison of body mass index among patients with versus without angiographic coronary artery disease. Am J Cardiol. 2007;100(1):18–22.
5.
BuettnerHJMuellerCGickM. The impact of obesity on mortality in UA/non-ST-segment elevation myocardial infarction. Eur Heart J. 2007;28(14):1694–1701.
6.
FaberDRde GrootPGVisserenFL. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes Rev. 2009;10(5):554–563.
7.
SowersJR. Obesity as a cardiovascular risk factor. Am J Med. 2003;115 suppl 8A:37S–41S.
8.
AttieADSchererPE. Adipocyte metabolism and obesity. J Lipid Res. 2009;50 suppl:S395–S399.
9.
DengYSchererPE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci. 2010;1212:E1–E19.
10.
KatsikiNAthyrosVGKaragiannisAMikhailidisDP. Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Curr Vasc Pharmacol. 2014;12(4):627–641.
11.
SoumayaK. Molecular mechanisms of insulin resistance in diabetes. Adv Exp Med Biol. 2012;771:240–251.
12.
KadoglouNPIliadisFAngelopoulouN. The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus. Eur J Cardiovasc Prev Rehabil. 2007;14(6):837–843.
13.
AthyrosVGTziomalosKKaragiannisAAnagnostisPMikhailidisDP. Should adipokines be considered in the choice of the treatment of obesity-related health problems?Curr Drug Targets. 2010;11(1):122–135.
14.
KatsikiNMikhailidisDPGotzamani-PsarrakouAYovosJGKaramitsosD. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin Ther Targets. 2011;15(4):401–420.
15.
KatsikiNNikolicDMontaltoGBanachMMikhailidisDPRizzoM. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des. 2013;19(17):3124–3131.
16.
GalicSOakhillJSSteinbergGR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316(2):129–139.
17.
TrujilloMESchererPE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev. 2006;27(7):762–778.
18.
AvramASAvramMMJamesWD. Subcutaneous fat in normal and diseased states: 2. Anatomy and physiology of white and brown adipose tissue. J Am Acad Dermatol. 2005;53(4):671–683.
19.
AilhaudG. Adipose tissue as a secretory organ: from adipogenesis to the metabolic syndrome. C R Biol. 2006;329(8):570–577.
20.
FurukawaSFujitaTShimabukuroM. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114(12):1752–1761.
21.
HosogaiNFukuharaAOshimaK. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007;56(4):901–911.
22.
PachlerCIkeokaDPlankJ. Subcutaneous adipose tissue exerts proinflammatory cytokines after minimal trauma in humans. Am J Physiol Endocrinol Metab. 2007;293(3):E690–E696.
23.
WeisbergSPMcCannDDesaiMRosenbaumMLeibelRLFerranteAWJr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–1808.
24.
OuchiNParkerJLLugusJJWalshK. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97.
25.
KatsikiNMikhailidisDPWierzbickiAS. Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol. 2013;28(4):458–463.
26.
de FeyterPJ. Epicardial adipose tissue: an emerging role for the development of coronary atherosclerosis. Clin Cardiol. 2011;34(3):143–144.
27.
van der GiessenAGGijsenFJWentzelJJ. Small coronary calcifications are not detectable by 64-slice contrast enhanced computed tomography. Int J Cardiovasc Imaging. 2011;27(1):143–152.
28.
de VosAMProkopMRoosCJ. Peri-coronary epicardial adipose tissue is related to cardiovascular risk factors and coronary artery calcification in post-menopausal women. Eur Heart J. 2008;29(6):777–783.
29.
GorterPMvan LindertASde VosAM. Quantification of epicardial and peri-coronary fat using cardiac computed tomography; reproducibility and relation with obesity and metabolic syndrome in patients suspected of coronary artery disease. Atherosclerosis. 2008;197(2):896–903.
30.
GreifMBeckerAvon ZieglerF. Pericardial adipose tissue determined by dual source ct is a risk factor for coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29(5):781–786.
31.
MahabadiAAMassaroJMRositoGA. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J. 2009;30(7):850–856.
32.
UenoKAnzaiTJinzakiM. Increased epicardial fat volume quantified by 64-multidetector computed tomography is associated with coronary atherosclerosis and totally occlusive lesions. Circ J. 2009;73(10):1927–1933.
33.
YongHSKimEJSeoHS. Pericardial fat is more abundant in patients with coronary atherosclerosis and even in the non-obese patients: evaluation with cardiac ct angiography. Int J Cardiovasc Imaging. 2010;26 suppl:153–162.
34.
KonishiMSugiyamaSSugamuraK. Association of pericardial fat accumulation rather than abdominal obesity with coronary atherosclerotic plaque formation in patients with suspected coronary artery disease. Atherosclerosis. 2010;209(2):573–578.
35.
HenrichotEJuge AubryCEPerninA. Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis?Arterioscler Thromb Vasc Biol. 2005;25(12):2594–2259.
36.
ShibasakiINishikimiTMochizukiY. Greater expression of inflammatory cytokines, adrenomedullin, and natriuretic peptide receptor-c in epicardial adipose tissue in coronary artery disease. Regul Pept. 2010;165(2-3):210–217.
37.
BakerARSilvaNFQuinnDW. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol. 2006;5:1.
38.
ChengKHChuCSLeeKT. Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int J Obes (Lond). 2008;32(2):268–274.
39.
GormezSDemirkanAAtalarF. Adipose tissue gene expression of adiponectin, tumor necrosis factor-alpha and leptin in metabolic syndrome patients with coronary artery disease. Intern Med. 2011;50(8):805–810.
40.
IacobellisGPistilliDGucciardoM. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine. 2005;29(6):251–255.
41.
MazurekTZhangLZalewskiA. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003;108(20):2460–2466.
42.
SchererPEWilliamsSFoglianoMBaldiniGLodishHF. A novel serum protein similar to c1q, produced exclusively in adipocytes. J Biol Chem. 1995;270(45):26746–26749.
43.
TakahashiMAritaYYamagataK. Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord. 2000;24(7):861–868.
44.
AritaYKiharaSOuchiN. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79–83.
45.
Hasan-AliHAbd El-MottalebNAHamedHBAbd-ElsayedA. Serum adiponectin and leptin as predictors of the presence and degree of coronary atherosclerosis. Coron Artery Dis. 2011;22(4):264–269.
46.
LiangKWSheuWHLeeWL. Decreased circulating protective adiponectin level is associated with angiographic coronary disease progression in patients with angina pectoris. Int J Cardiol. 2008;129(1):76–80.
47.
ErogluSSadeLEBozbasH. Association of serum adiponectin levels and coronary flow reserve in women with normal coronary angiography. Eur J Cardiovasc Prev Rehabil. 2009;16(3):290–296.
48.
KojimaSFunahashiTSakamotoT. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart. 2003;89(6):667.
49.
PischonTGirmanCJHotamisligilGSRifaiNHuFBRimmEB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291(14):1730–1737.
50.
SchulzeMBShaiIRimmEBLiTRifaiNHuFB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 2005;54(2):534–539.
51.
MatsuzawaYFunahashiTKiharaSShimomuraI. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24(1):29–33.
52.
BobbertTRochlitzHWegewitzU. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes. 2005;54(9):2712–2719.
53.
PajvaniUBDuXCombsTP. Structure–function studies of the adipocyte-secreted hormone acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem. 2003;278(11):9073–9085.
54.
EbinumaHMiyazakiOYagoHHaraKYamauchiTKadowakiT. A novel ELISA system for selective measurement of human adiponectin multimers by using proteases. Clin Chim Acta. 2006;372(1-2):47–53.
55.
Lara-CastroCLuoNWallacePKleinRLGarveyWT. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes. 2006;55(1):249–259.
56.
MurdoloGNowotnyBCeliF. Inflammatory adipokines, high molecular weight adiponectin, and insulin resistance: a population-based survey in prepubertal schoolchildren. PLoS One. 2011;6(2):e17264.
57.
StofkovaA. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul. 2009;43(4):157–168.
58.
YamauchiTKamonJWakiH. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem. 2003;278(4):2461–2468.
59.
HugCWangJAhmadNSBoganJSTsaoTSLodishHF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA. 2004;101(28):10308–10313.
60.
DoyleDDGoingsGEUpshaw-EarleyJPageERanschtBPalfreyHC. T-cadherin is a major glycophosphoinositol-anchored protein associated with noncaveolar detergent-insoluble domains of the cardiac sarcolemma. J Biol Chem. 1998;273(12):6937–6943.
61.
FujiokaDKawabataKSaitoY. Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. Am J Physiol Heart Circ Physiol. 2006;290(6):H2409–H24016.
62.
YamauchiTNioYMakiT. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13(3):332–339.
63.
TanKCXuAChowWS. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab. 2004;89(2):765–769.
64.
FesusGDubrovskaGGorzelniakK. Adiponectin is a novel humoral vasodilator. Cardiovasc Res. 2007;75(4):719–727.
65.
XiWSatohHKaseHSuzukiKHattoriY. Stimulated HSP90 binding to eNOS and activation of the PI3-Akt pathway contribute to globular adiponectin-induced no production: vasorelaxation in response to globular adiponectin. Biochem Biophys Res Commun. 2005;332(1):200–205.
66.
GreensteinASKhavandiKWithersSB. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation. 2009;119(12):1661–1670.
67.
ChenXZhangHMcAfeeSZhangC. The reciprocal relationship between adiponectin and LOX-1 in the regulation of endothelial dysfunction in ApoE knockout mice. Am J Physiol Heart Circ Physiol. 2010;299(3):H605–H612.
68.
OuedraogoRGongYBerzinsB. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest. 2007;117(6):1718–1726.
69.
OuchiNKiharaSAritaY. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100(25):2473–2476.
70.
AritaYKiharaSOuchiN. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002;105(24):2893–2898.
71.
CaiXJChenLLiL. Adiponectin inhibits lipopolysaccharide-induced adventitial fibroblast migration and transition to myofibroblasts via AdipoR1-AMPK-iNOS pathway. Mol Endocrinol. 2010;24(1):218–228.
72.
OuchiNKiharaSAritaY. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class a scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103(8):1057–1063.
OkamotoYKiharaSOuchiN. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002;106(22):2767–2770.
75.
OkamotoYFolcoEJMinamiM. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res. 2008;102(2):218–225.
76.
KatoHKashiwagiHShiragaM. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol. 2006;26(1):224–230.
77.
HallJE. The kidney, hypertension, and obesity. Hypertension. 2003;41(3 pt 2):625–633.
78.
KimDHKimCDingELTownsendMKLipsitzLA. Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension. 2013;62(1):27–32.
79.
ShibataROuchiNItoM. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med. 2004;10(12):1384–1389.
80.
KadowakiTYamauchiT. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439–451.
81.
KarmazynMPurdhamDMRajapurohitamVZeidanA. Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart. Cardiovasc Res. 2008;79(2):279–286.
82.
OuchiNShibataRWalshK. Cardioprotection by adiponectin. Trends Cardiovasc Med. 2006;16(5):141–146.
83.
ShibataRSatoKPimentelDR. Adiponectin protects against myocardial ischemia–reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 2005;11(10):1096–1103.
84.
ZhangYProencaRMaffeiMBaroneMLeopoldLFriedmanJM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425–432.
PelleymounterMACullenMJBakerMB. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995;269(5223):540–543.
87.
DieguezCVazquezMJRomeroALopezMNogueirasR. Hypothalamic control of lipid metabolism: focus on leptin, ghrelin and melanocortins. Neuroendocrinology. 2011;94(1):1–11.
MantzorosCSMagkosFBrinkoetterM. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab. 2011;301(4):E567–E584.
90.
CaroJFSinhaMKKolaczynskiJWZhangPLConsidineRV. Leptin: the tale of an obesity gene. Diabetes. 1996;45(11):1455–1462.
91.
ZabeauLLavensDPeelmanFEyckermanSVandekerckhoveJTavernierJ. The ins and outs of leptin receptor activation. FEBS Lett. 2003;546(1):45–50.
92.
MinokoshiYKimYBPeroniOD. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002;415(6869):339–343.
93.
RenJ. Leptin and hyperleptinemia—from friend to foe for cardiovascular function. J Endocrinol. 2004;181(1):1–10.
94.
SahuA. Minireview: a hypothalamic role in energy balance with special emphasis on leptin. Endocrinology. 2004;145(6):2613–2620.
95.
FruhbeckG. Intracellular signalling pathways activated by leptin. Biochem J. 2006;393(pt 1):7–20.
96.
MargeticSGazzolaCPeggGGHillRA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002;26(11):1407–1433.
97.
GnacinskaMMalgorzewiczSStojekMLysiak-SzydlowskaWSworczakK. Role of adipokines in complications related to obesity: a review. Adv Med Sci. 2009;54(2):150–157.
98.
ConsidineRVSinhaMKHeimanML. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292–295.
WaumanJTavernierJ. Leptin receptor signaling: pathways to leptin resistance. Front Biosci (Landmark Ed). 2011;16:2771–2793.
101.
SoderbergSAhrenBJanssonJH. Leptin is associated with increased risk of myocardial infarction. J Intern Med. 1999;246(4):409–418.
102.
SoderbergSAhrenBStegmayrB. Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke. 1999;30(2):328–337.
103.
TaneliFYeganeSUlmanC. Increased serum leptin concentrations in patients with chronic stable angina pectoris and ST-elevated myocardial infarction. Angiology. 2006;57(3):267–272.
104.
WallaceAMMcMahonADPackardCJ. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001;104(25):3052–3056.
105.
WolkRBergerPLennonRJBrilakisESJohnsonBDSomersVK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol. 2004;44(9):1819–1824.
106.
PiattiPDi MarioCMontiLD. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation. 2003;108(17):2074–2081.
107.
NorataGDRaselliSGrigoreL. Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke. 2007;38(10):2844–2846.
108.
BeltowskiJ. Leptin and atherosclerosis. Atherosclerosis. 2006;189(1):47–60.
109.
LemboGVecchioneCFrattaL. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes. 2000;49(2):293–297.
110.
VecchioneCMaffeiAColellaS. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes. 2002;51(1):168–173.
111.
BeltowskiJ. Leptin and the regulation of endothelial function in physiological and pathological conditions. Clin Exp Pharmacol Physiol. 2012;39(2):168–178.
KonstantinidesSSchaferKKoschnickSLoskutoffDJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest. 2001;108(10):1533–1540.
114.
BodaryPFWestrickRJWickenheiserKJShenYEitzmanDT. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA. 2002;287(13):1706–1709.
115.
BodaryPFGuSShenYHastyAHBucklerJMEitzmanDT. Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25(8):e119–e122.
116.
CirilloPAngriVDe RosaS. Pro-atherothrombotic effects of leptin in human coronary endothelial cells. Thromb Haemost. 2010;103(5):1065–1075.
117.
NapoleoneEDISAAmoreC. Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk?J Thromb Haemost. 2007;5(7):1462–1468.
118.
BouloumieAMarumoTLafontanMBusseR. Leptin induces oxidative stress in human endothelial cells. FASEB J. 1999;13(10):1231–1238.
119.
SchaferKKonstantinidesS. Mechanisms linking leptin to arterial and venous thrombosis: potential pharmacological targets. Curr Pharm Des. 2014;20(4):635-640.
120.
De RosaSCirilloPPacileoMDi PalmaVPagliaAChiarielloM. Leptin stimulated C-reactive protein production by human coronary artery endothelial cells. J Vasc Res. 2009;46(6):609–617.
121.
CirilloPGolinoPCalabroP. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res. 2005;68(1):47–55.
122.
ZeadinMButcherMWerstuckGKhanMYeeCKShaughnessySG. Effect of leptin on vascular calcification in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2009;29(12):2069–2075.
123.
ChibaTShinozakiSNakazawaT. Leptin deficiency suppresses progression of atherosclerosis in apoE-deficient mice. Atherosclerosis. 2008;196(1):68–75.
124.
NickolaMWWoldLEColliganPBWangGJSamsonWKRenJ. Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of no. Hypertension. 2000;36(4):501–505.
125.
DongFZhangXRenJ. Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. Hypertension. 2006;47(2):222–229.
126.
MadaniSDe GirolamoSMunozDMLiRKSweeneyG. Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc Res. 2006;69(3):716–725.
127.
RajapurohitamVGanXTKirshenbaumLAKarmazynM. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res. 2003;93(4):277–279.
128.
TajmirPCeddiaRBLiRKCoeIRSweeneyG. Leptin increases cardiomyocyte hyperplasia via extracellular signal-regulated kinase- and phosphatidylinositol 3-kinase-dependent signaling pathways. Endocrinology. 2004;145(4):1550–1555.
129.
HalestrapAPClarkeSJJavadovSA. Mitochondrial permeability transition pore opening during myocardial reperfusion—a target for cardioprotection. Cardiovasc Res. 2004;61(3):372–385.
130.
ErkasapNIkizlerMShneyvaysV. Leptin protects the cardiac myocyte cultures from hypoxic damage. Life Sci. 2006;78(10):1098–1102.
131.
SmithCCMocanuMMDavidsonSMWynneAMSimpkinJCYellonDM. Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. Br J Pharmacol. 2006;149(1):5–13.
132.
SmithCCDixonRAWynneAM. Leptin-induced cardioprotection involves JAK/STAT signaling that may be linked to the mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol. 2010;299(4):H1265–H1270.
133.
PurdhamDMZouMXRajapurohitamVKarmazynM. Rat heart is a site of leptin production and action. Am J Physiol Heart Circ Physiol. 2004;287(6):H2877–H2884.
134.
SteppanCMBrownEJWrightCM. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA. 2001;98(2):502–506.
135.
AdeghateE. An update on the biology and physiology of resistin. Cell Mol Life Sci. 2004;61(19-20):2485–2496.
136.
FilkovaMHaluzikMGaySSenoltL. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol. 2009;133(2):157–170.
137.
SteppanCMBaileySTBhatS. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307–312.
138.
YaturuSDaberryRPRainsJJainS. Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes. Cytokine. 2006;34(3-4):219–223.
139.
BurnettMSLeeCWKinnairdTD. The potential role of resistin in atherogenesis. Atherosclerosis. 2005;182(2):241–248.
140.
ReillyMPLehrkeMWolfeMLRohatgiALazarMARaderDJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111(7):932–939.
141.
RajalaMWQiYPatelHR. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes. 2004;53(7):1671–1679.
142.
QiYNieZLeeYS. Loss of resistin improves glucose homeostasis in leptin deficiency. Diabetes. 2006;55(11):3083–3090.
143.
KunnariAUkkolaOPaivansaloMKesaniemiYA. High plasma resistin level is associated with enhanced highly sensitive c-reactive protein and leukocytes. J Clin Endocrinol Metab. 2006;91(7):2755–2760.
144.
LubosEMessowCMSchnabelR. Resistin, acute coronary syndrome and prognosis results from the atherogene study. Atherosclerosis. 2007;193(1):121–128.
145.
NorataGDOngariMGarlaschelliKRaselliSGrigoreLCatapanoAL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol. 2007;156(2):279–284.
146.
WangHChenDYCaoJHeZYZhuBPLongM. High serum resistin level may be an indicator of the severity of coronary disease in acute coronary syndrome. Chin Med Sci J. 2009;24(3):161–166.
147.
PischonTBambergerCMKratzschJ. Association of plasma resistin levels with coronary heart disease in women. Obes Res. 2005;13(10):1764–1771.
148.
ChuSDingWLiKPangYTangC. Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J. 2008;72(8):1249–1253.
149.
LangheimSDreasLVeschiniL. Increased expression and secretion of resistin in epicardial adipose tissue of patients with acute coronary syndrome. Am J Physiol Heart Circ Physiol. 2010;298(3):H746–H753.
150.
EfstathiouSPTsiakouAGTsioulosDI. Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin Chim Acta. 2007;378(1-2):78–85.
151.
VermaSLiSHWangCH. Resistin promotes endothelial cell activation: further evidence of adipokine–endothelial interaction. Circulation. 2003;108(6):736–740.
152.
LiYWangYLiQ. Effect of resistin on vascular endothelium secretion dysfunction in rats. Endothelium. 2007;14(4-5):207–214.
153.
CalabroPSamudioIWillersonJTYehET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation. 2004;110(21):3335–3340.
154.
JungHSParkKHChoYM. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res. 2006;69(1):76–85.
155.
CalabroPCirilloPLimongelliG. Tissue factor is induced by resistin in human coronary artery endothelial cells by the NF-κB-dependent pathway. J Vasc Res. 2011;48(1):59–66.
156.
FukuharaAMatsudaMNishizawaM. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426–430.
157.
SamalBSunYStearnsGXieCSuggsSMcNieceI. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994;14(2):1431–1437.
158.
RongvauxASheaRJMulksMH. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyl transferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol. 2002;32(11):3225–3234.
159.
TanBKChenJDigbyJEKeaySDKennedyCRRandevaHS. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab. 2006;91(12):5022–5028.
160.
BerndtJKlotingNKralischS. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005;54(10):2911–2916.
161.
WangPXuTYGuanYFSuDFFanGRMiaoCY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res. 2009;81(2):370–380.
162.
Saddi-RosaPOliveiraCSGiuffridaFMReisAF. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr. 2010;2:21.
163.
WangZNakayamaT. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm. 2010;2010:535918.
164.
KadoglouNPSailerNMoumtzouoglouA. Visfatin (NAMPT) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2010;118(2):75–80.
165.
ZhongMTanHWGongHPWangSFZhangYZhangW. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf). 2008;69(6):878–884.
166.
LiuSWQiaoSBYuanJSLiuDQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf). 2009;71(2):202–207.
167.
DahlTBYndestadASkjellandM. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007;115(8):972–980.
168.
SpiroglouSGKostopoulosCGVarakisJNPapadakiHH. Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J Atheroscler Thromb. 2010;17(2):115–130.
169.
LuL-FWangC-PYuT-H. Interpretation of elevated plasma visfatin concentrations in patients with ST-elevation myocardial infarction. Cytokine. 2012;57(1):74–80.
170.
AdyaRTanBKPunnAChenJRandevaHS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 2008;78(2):356–365.
171.
YamawakiHHaraNOkadaMHaraY. Visfatin causes endothelium-dependent relaxation in isolated blood vessels. Biochem Biophys Res Commun. 2009;383(4):503–508.
172.
TakebayashiKSuetsuguMWakabayashiSAsoYInukaiT. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism. 2007;56(4):451–458.
173.
KimSRBaeYHBaeSK. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta. 2008;1783(5):886–895.
174.
CirilloPDi PalmaVMarescaF. The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells: another piece in the adipokines puzzle. Thromb Res. 2012;130(3):403–408.
175.
MoschenARKaserAEnrichB. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178(3):1748–1758.
176.
LimSYDavidsonSMParamanathanAJSmithCCYellonDMHausenloyDJ. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med. 2008;12(4):1395–1403.
177.
O'DowdBFHeiberMChanA. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993;136(1-2):355–360.
178.
TatemotoKHosoyaMHabataY. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251(2):471–476.
179.
KawamataYHabataYFukusumiS. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta. 2001;1538(2-3):162–171.
180.
LeeDKSaldiviaVRNguyenTChengRGeorgeSRO'DowdBF. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology. 2005;146(1):231–236.
181.
LeeDKGeorgeSRO'DowdBF. Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci. 2006;27(4):190–194.
182.
Castan-LaurellIVitkovaMDaviaudD. Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol. 2008;158(6):905–910.
183.
KleinzMJSkepperJNDavenportAP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005;126(3):233–240.
184.
KleinzMJDavenportAP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept. 2004;118(3):119–125.
185.
BoucherJMasriBDaviaudD. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005;146(4):1764–1771.
186.
KadoglouNPLampropoulosSKapelouzouA. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease—kozani study. Transl Res. 2010;155(5):238–246.
187.
WeirRAChongKSDalzellJR. Plasma apelin concentration is depressed following acute myocardial infarction in man. Eur J Heart Fail. 2009;11(6):551–558.
188.
YeJNiPKangLXuB. Apelin and vascular endothelial growth factor are associated with mobilization of endothelial progenitor cells after acute myocardial infarction. J Biomed Res. 2012;26(6):400–409.
189.
KuklinskaAMSobkowiczBSawickiR. Apelin: a novel marker for the patients with first ST-elevation myocardial infarction. Heart Vessels. 2010;25(5):363–367.
190.
TycinskaAMSobkowiczBMroczkoB. The value of apelin-36 and brain natriuretic peptide measurements in patients with first ST-elevation myocardial infarction. Clin Chim Acta. 2010;411(23-24):2014–2018.
191.
TasciIDogruTNaharciI. Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes. 2007;115(7):428–432.
192.
SonmezACelebiGErdemG. Plasma apelin and ADMA levels in patients with essential hypertension. Clin Exp Hypertens. 2010;32(3):179–183.
193.
RittigKHildebrandtUThamerC. Apelin serum levels are not associated with early atherosclerosis or fat distribution in young subjects with increased risk for type 2 diabetes. Exp Clin Endocrinol Diabetes. 2011;119(6):358–361.
194.
PitkinSLMaguireJJKucREDavenportAP. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br J Pharmacol. 2010;160(7):1785–1795.
195.
LiFLiLQinX. Apelin-induced vascular smooth muscle cell proliferation: the regulation of cyclin D1. Front Biosci. 2008;13:3786–3792.
196.
KojimaYKunduRKCoxCM. Upregulation of the apelin–APJ pathway promotes neointima formation in the carotid ligation model in mouse. Cardiovasc Res. 2010;87(1):156–165.
197.
LuYZhuXLiangGX. Apelin–APJ induces ICAM-1, VCAM-1 and MCP-1 expression via NF-kappaB/JNK signal pathway in human umbilical vein endothelial cells. Amino Acids. 2012;43(5):2125–2136.
198.
HashimotoTKiharaMImaiN. Requirement of apelin–apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol. 2007;171(5):1705–1712.
199.
ChunHJAliZAKojimaY. Apelin signaling antagonizes ANG II effects in mouse models of atherosclerosis. J Clin Invest. 2008;118(10):3343–3354.
200.
ShanPFLuYCuiRRJiangYYuanLQLiaoEY. Apelin attenuates the osteoblastic differentiation of vascular smooth muscle cells. PLoS One. 2011;6(3):e17938.
201.
TatemotoKTakayamaKZouMX. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;99(2-3):87–92.
202.
IshidaJHashimotoTHashimotoY. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem. 2004;279(25):26274–26279.
203.
ChengXChengXSPangCC. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol. 2003;470(3):171–175.
204.
AshleyEAPowersJChenM. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res. 2005;65(1):73–82.
205.
ZhangQYaoFRaizadaMKO'RourkeSTSunC. Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats. Circ Res. 2009;104(12):1421–1428.
206.
NaganoKIshidaJUnnoMMatsukuraTFukamizuA. Apelin elevates blood pressure in ICR mice with l-NAME-induced endothelial dysfunction. Mol Med Rep. 2013;7(5):1371–1375.
207.
JiaYXLuZFZhangJ. Apelin activates l-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides. 2007;28(10):2023–2039.
208.
KagiyamaSFukuharaMMatsumuraKLinYFujiiKIidaM. Central and peripheral cardiovascular actions of apelin in conscious rats. Regul Pept. 2005;125(1-3):55–59.
209.
SeyedabadiMGoodchildAKPilowskyPM. Site-specific effects of apelin-13 in the rat medulla oblongata on arterial pressure and respiration. Auton Neurosci. 2002;101(1-2):32–38.
210.
IwanagaYKiharaYTakenakaHKitaT. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin II–angiotensin type 1 receptor system. J Mol Cell Cardiol. 2006;41(5):798–806.
211.
RonkainenVPRonkainenJJHanninenSL. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J. 2007;21(8):1821–1830.
212.
AtluriPMorineKJLiaoGP. Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett. 2007;12(1):127–138.
213.
ZhangJRenCXQiYF. Exercise training promotes expression of apelin and APJ of cardiovascular tissues in spontaneously hypertensive rats. Life Sci. 2006;79(12):1153–1159.
214.
HiguchiKMasakiTGotohK. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology. 2007;148(6):2690–2697.
215.
BerryMFPirolliTJJayasankarV. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation. 2004;110(11 suppl 1):II187–II193.
216.
SzokodiITaviPFoldesG. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 2002;91(5):434–440.
ChongKSGardnerRSMortonJJAshleyEAMcDonaghTA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail. 2006;8(4):355–360.
219.
EllinorPTLowAFMacraeCA. Reduced apelin levels in lone atrial fibrillation. Eur Heart J. 2006;27(2):222–226.
220.
FranciaPSalvatiABallaC. Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur J Heart Fail. 2007;9(3):306–309.
221.
de Souza BatistaCMYangRZLeeMJ. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007;56(6):1655–1661.
222.
PanHYGuoLLiQ. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract. 2010;88(1):29–33.
223.
YangRZLeeMJHuH. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab. 2006;290(6):E1253–E1261.
224.
ShangFJWangJPLiuXT. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers. 2011;16(8):657–662.
225.
ShibataROuchiNKikuchiR. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis. 2011;219(2):811–814.
226.
ZhongXZhangHYTanH. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin. 2011;32(7):873–878.
227.
LiuRWangXBuP. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract. 2011;93(1):21–25.
228.
DuanXYXiePLMaYLTangSY. Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the Pi3k/Akt pathway. Amino Acids. 2011;41(5):1223–1231.
229.
YooHJHwangSYHongHC. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol. 2011;10103.
230.
YamawakiHTsubakiNMukohdaMOkadaMHaraY. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun. 2010;393(4):668–672.
231.
TanBKAdyaRRandevaHS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med. 2010;20(5):143–148.
232.
GreulichSChenWJMaxheraB. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PLoS One. 2013;8(3):e59697.
233.
KlotingNBerndtJKralischS. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun. 2006;339(1):430–436.
234.
ChoJKHanTKKangHS. Combined effects of body mass index and cardio/respiratory fitness on serum vaspin concentrations in Korean young men. Eur J Appl Physiol. 2010;108(2):347–353.
235.
YounBSKlotingNKratzschJ. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008;57(2):372–377.
236.
YeYHouXHPanXPLuJXJiaWP. Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes. Chin Med J (Engl). 2009;122(21):2530–2533.
237.
LagoFDieguezCGomez-ReinoJGualilloO. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev. 2007;18(3-4):313–325.
238.
HidaKWadaJEguchiJ. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA. 2005;102(30):10610–10615.
239.
SeegerJZiegelmeierMBachmannA. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab. 2008;93(1):247–251.
240.
LiHLPengWHCuiST. Vaspin plasma concentrations and mRNA expressions in patients with stable and unstable angina pectoris. Clin Chem Lab Med. 2011;49(9):1547–1554.
241.
AustGRichterORohmS. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis. 2009;204(1):262–266.
242.
JungCHLeeWJHwangJY. Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun. 2011;413(2):264–269.
243.
VaspinWada J.. A novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs. 2008;17(3):327–333.
244.
PhalitakulSOkadaMHaraYYamawakiH. Vaspin prevents TNF-alpha-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependent NF-kappaB and PKCtheta activation in cultured rat vascular smooth muscle cells. Pharmacol Res. 2011;64(5):493–500.
245.
KotnikPFischer-PosovszkyPWabitschM. Rbp4: a controversial adipokine. Eur J Endocrinol. 2011;165(5):703–711.
246.
ColantuoniVRomanoVBensiG. Cloning and sequencing of a full length cDNA coding for human retinol-binding protein. Nucleic Acids Res. 1983;11(22):7769–7776.
247.
BlanerWS. Retinol-binding protein: the serum transport protein for vitamin a. Endocr Rev. 1989;10(3):308–316.
248.
TsutsumiCOkunoMTannousL. Retinoids and retinoid-binding protein expression in rat adipocytes. J Biol Chem. 1992;267(3):1805–1810.
249.
ZovichDCOrologaAOkunoM. Differentiation-dependent expression of retinoid-binding proteins in BFC-1 beta adipocytes. J Biol Chem. 1992;267(20):13884–13889.
250.
KellyKRKashyapSRO'LearyVBMajorJSchauerPRKirwanJP. Retinol-binding protein 4 (RBP4) protein expression is increased in omental adipose tissue of severely obese patients. Obesity (Silver Spring). 2010;18(4):663–666.
251.
KlotingNGrahamTEBerndtJ. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab. 2007;6(1):79–87.
252.
ErikstrupCMortensenOHNielsenAR. RBP-to-retinol ratio, but not total RBP, is elevated in patients with type 2 diabetes. Diabetes Obes Metab. 2009;11(3):204–212.
253.
SivaprasadaraoAFindlayJB. The interaction of retinol-binding protein with its plasma-membrane receptor. Biochem J. 1988;255(2):561–569.
254.
MatareseVLodishHF. Specific uptake of retinol-binding protein by variant F9 cell lines. J Biol Chem. 1993;268(25):18859–18865.
255.
KawaguchiRYuJHondaJ. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. Science. 2007;315(5813):820–825.
256.
ChambonP. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996;10(9):940–954.
257.
YangQGrahamTEModyN. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436(7049):356–362.
258.
GrahamTEYangQBluherM. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006;354(24):2552–2563.
259.
BalagopalPGrahamTEKahnBBAltomareAFunanageVGeorgeD. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab. 2007;92(5):1971–1974.
260.
HermsdorffHHZuletMAPuchauBMartinezJA. Central adiposity rather than total adiposity measurements are specifically involved in the inflammatory status from healthy young adults. Inflammation. 2011;34(3):161–170.
261.
HaiderDGSchindlerKPragerG. Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab. 2007;92(3):1168–1171.
262.
JankeJEngeliSBoschmannM. Retinol-binding protein 4 in human obesity. Diabetes. 2006;55(10):2805–2810.
263.
LeeJWLeeHRShimJYImJALeeDC. Abdominal visceral fat reduction is associated with favorable changes of serum retinol binding protein-4 in nondiabetic subjects. Endocr J. 2008;55(5):811–818.
264.
VitkovaMKlimcakovaEKovacikovaM. Plasma levels and adipose tissue messenger ribonucleic acid expression of retinol-binding protein 4 are reduced during calorie restriction in obese subjects but are not related to diet-induced changes in insulin sensitivity. J Clin Endocrinol Metab. 2007;92(6):2330–2335.
265.
ChoYMYounBSLeeH. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care. 2006;29(11):2457–2461.
266.
KlotingNFasshauerMDietrichA. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab. 2010;299(3):E506–E515.
267.
Ribel-MadsenRFriedrichsenMVaagAPoulsenP. Retinol-binding protein 4 in twins: regulatory mechanisms and impact of circulating and tissue expression levels on insulin secretion and action. Diabetes. 2009;58(1):54–60.
268.
Yao-BorengasserAVarmaVBodlesAM. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab. 2007;92(7):2590–2597.
269.
ChristouGATselepisADKiortsisDN. The metabolic role of retinol binding protein 4: an update. Horm Metab Res. 2012;44(1):6–14.
270.
IngelssonESundstromJMelhusH. Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. Atherosclerosis. 2009;206(1):239–244.
271.
LimSYoonJWChoiSH. Combined impact of adiponectin and retinol-binding protein 4 on metabolic syndrome in elderly people: the Korean longitudinal study on health and aging. Obesity (Silver Spring). 2010;18(4):826–832.
272.
MakinoSFujiwaraMSuzukawaK. Visceral obesity is associated with the metabolic syndrome and elevated plasma retinol binding protein-4 level in obstructive sleep apnea syndrome. Horm Metab Res. 2009;41(3):221–226.
273.
QiQYuZYeX. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab. 2007;92(12):4827–4834.
274.
LinCCLaiMMLiTC. Relationship between serum retinol-binding protein 4 and visfatin and the metabolic syndrome. Diabetes Res Clin Pract. 2009;85(1):24–29.
275.
ParkSEKimDHLeeJH. Retinol-binding protein-4 is associated with endothelial dysfunction in adults with newly diagnosed type 2 diabetes mellitus. Atherosclerosis. 2009;204(1):23–25.
276.
IngelssonELindL. Circulating retinol-binding protein 4 and subclinical cardiovascular disease in the elderly. Diabetes Care. 2009;32(4):733–735.
277.
SoliniASantiniEMadecSRossiCMuscelliE. Retinol-binding protein-4 in women with untreated essential hypertension. Am J Hypertens. 2009;22(9):1001–1006.
278.
BobbertTRailaJSchwarzF. Relation between retinol, retinol-binding protein 4, transthyretin and carotid intima media thickness. Atherosclerosis. 2010;213(2):549–551.
279.
CabreALazaroIGironaJ. Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. J Intern Med. 2007;262(4):496–503.
280.
MallatZSimonTBenessianoJ. Retinol-binding protein 4 and prediction of incident coronary events in healthy men and women. J Clin Endocrinol Metab. 2009;94(1):255–260.
281.
FabbriniESullivanSKleinS. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679–689.
282.
Mendez-SanchezNArreseMZamora-ValdesDUribeM. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int. 2007;27(4):423–433.
283.
MarchesiniGBriziMBianchiG. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8):1844–1850.
284.
TonjesABluherMStumvollM. Retinol-binding protein 4 and new adipocytokines in nonalcoholic fatty liver disease. Curr Pharm Des. 2010;16(17):1921–1928.
285.
PolyzosSAToulisKAGoulisDGZavosCKountourasJ. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011;60(3):313–326.
286.
WreeAKahramanAGerkenGCanbayA. Obesity affects the liver—the link between adipocytes and hepatocytes. Digestion. 2011;83(1-2):124–133.
287.
TilgH. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):179–185.
288.
PolyzosSAKountourasJZavosCTsiaousiE. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2010;12(5):365–383.
289.
ChitturiSFarrellGFrostL. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?Hepatology. 2002;36(2):403–409.
290.
PaganoCSoardoGPilonC. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab. 2006;91(3):1081–1086.
291.
PerseghinGBonfantiRMagniS. Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease. Am J Physiol Endocrinol Metab. 2006;291(4):E697–E703.
292.
SchinaMKoskinasJTiniakosD. Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease. Hepatol Res. 2009;39(10):972–928.
293.
StefanNHennigeAMStaigerH. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care. 2007;30(5):1173–1178.
294.
AlkhouriNLopezRBerkMFeldsteinAE. Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol. 2009;43(10):985–989.
295.
JarrarMHBaranovaACollantesR. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27(5):412–421.
